Effect of isosorbide-5-mononitrate on plasma and urine levels of cyclic GMP in relation to exercise in coronary patients compared with control subjects

European Journal of Clinical Investigation
J R BerrazuetaJ Poveda

Abstract

Nitric oxide (NO) and atrial natriuretic peptide (ANP) relax vascular smooth muscle increasing levels of cyclic guanosine 3':5' monophosphate (cGMP). Nitrovasodilators act as exogenous nitric oxide donors. The aim of this study was to ascertain the response of cGMP to exercise without medication and after the administration of 20 mg of isosorbide-5-mononitrate (IS-5-MN) in coronary patients (n = 8) and healthy control subjects (n = 9). A third group of 10 normal volunteers was studied to test plasma cGMP response to second exercise test without IS-5-MN administration. Plasma cGMP increased significantly in both patients (P < 0.02) and controls (P < 0.01) after the first ergometry. After IS-5-MN administration, plasma cGMP did not increase either before or after exercise. In normal volunteers without IS-5-MN plasma cGMP increased significantly after first (P < 0.004) and second (P < 0.0008) exercise test. In conclusion, plasma cGMP increases during exercise. Administration of IS-5-MN does not raise plasma cGMP and neither does performance of further exercise after its administration.

References

Dec 1, 1979·Naunyn-Schmiedeberg's Archives of Pharmacology·W R KukovetzG Pöch
Nov 1, 1992·Diabetic Medicine : a Journal of the British Diabetic Association·E SalasJ Amado
Sep 24, 1992·The American Journal of Cardiology·E Bassenge, J Zanzinger
Sep 24, 1992·The American Journal of Cardiology·J O Parker, J D Parker
Nov 1, 1990·British Journal of Pharmacology·D D ReesS Moncada
Mar 1, 1991·Electroencephalography and Clinical Neurophysiology·S TobimatsuM Kato
Mar 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·S MoncadaR M Palmer
May 1, 1990·Hypertension·T F Lüscher
Apr 1, 1990·Canadian Journal of Physiology and Pharmacology·G A SagnellaP Hamet
Jun 1, 1990·Gastroenterologia Japonica·S MiyaseT Sato
May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·D D ReesS Moncada
May 1, 1989·Biological Chemistry Hoppe-Seyler·A Savel-Niemann
Oct 15, 1986·Biochemical Pharmacology·S A WaldmanF Murad
Nov 15, 1986·The American Journal of Cardiology·T NishikimiT Takeda
Oct 1, 1988·Hypertension·S MoncadaE A Higgs
Jan 1, 1988·European Heart Journal·M G Bogaert
Mar 1, 1987·Neurotoxicology and Teratology·S Norton, B F Kimler
Apr 1, 1987·The American Journal of Cardiology·U ThadaniS M Teague
Aug 7, 1985·European Journal of Pharmacology·Y Shirasaki, C Su
Jan 1, 1972·Naunyn-Schmiedeberg's Archives of Pharmacology·M G Bogaert, M T Rosseel
Jan 1, 1981·European Journal of Clinical Pharmacology·U Abshagen, S Spörl-Radun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.